SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
| Revenue (TTM) | $20.34M |
| Gross Profit (TTM) | $20.34M |
| EBITDA | $-36.54M |
| Operating Margin | -120.00% |
| Return on Equity | -53.40% |
| Return on Assets | -21.00% |
| Revenue/Share (TTM) | $3.23 |
| Book Value | $5.33 |
| Price-to-Book | 1.06 |
| Price-to-Sales (TTM) | 2.25 |
| EV/Revenue | 0.0596 |
| EV/EBITDA | 0.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1809.00% |
| Shares Outstanding | $79.44M |
| Float | $7.70M |
| % Insiders | 2.00% |
| % Institutions | 53.31% |
Volatility is currently contracting
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.
SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026
JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.
